GT Biopharma (NASDAQ: GTBP), focused on the development and commercialization of its disruptive, target-directed Natural Killer (“NK”) cell engager immunotherapy protein biologic platform technology: TriKE(TM) for cancer and infectious diseases, has closed an underwritten public offering of 4,945,000 units. According to the update, the offering includes an additional 645,000 units pursuant to the full exercise of the over-allotment option granted to the underwriters. GT Biopharma secured approximately $27.2 million in gross proceeds, with each unit consisting of one share of GT Biopharma’s common stock and one warrant to purchase one share of common stock sold at a public offering price of $5.50. ROTH Capital Partners acted as joint book-running manager for the offering.
To view the full press release, visit https://ibn.fm/wI4YB
About GT Biopharma Inc.
GT Biopharma is a clinical stage biopharmaceutical company focused on the development and commercialization of immunology therapeutic products based on its proprietary Trispecific Killer Engagers (“TriKE(TM)”) target-directed Natural Killer (“NK”) cell engager platform. The TriKE NK protein biologic platform is designed to harness and amplify the body’s native immune system for hope for patients with cancer and infectious diseases. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota, where Jeffery S. Miller, M.D., GT Biopharma’s consulting chief medical officer, developed the TriKE to further develop and commercialize therapies using TriKE technology. For more information, please visit www.GTBiopharma.com
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.